While GLP-1 receptor agonists represent the most established and studied pharmacologic adjuncts to EBTs, other anti-obesity agents, including phentermine/topiramate and bupropion/naltrexone, could theoretically be combined with endoscopic interventions. The gene discussed is GLP1R; the disease is Obesity.